الفهرس 
Title : Role of neoadjuvant combination chemotherapy followed by chemoradiotherapy for patients with rectal cancer
AbstractOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Background Evaluation of the safety and efficacy of neoadjuvant chemotherapy for 2 months followed bychemoradiation in middle and lower third rectal cancer patients. Patients and methods This is a prospective, single-arm, phase-II study, carried out on 41 patients with middle and lower third of rectal cancer from 1 January 2016 to 31 July 2018. Patients received 2 months induction FOLFIRINOX chemotherapy, consisted of Oxaliplatin 85 mg/m2 over 2 hours day 1, Leucovorin 400 mg/m2 over 2 hours day 1, Irinotecan 180 mg/m2 over 2 hours day 1, bolus 5-Fluorouracil 5FU 400 mg/m2 day 1, infusion 5FU 2400 mg/m2 over 46 h, every 14 day, followed by concomitant chemoradiotherapy (CRT) consisted of 5-Fluorouracil 400 mg/m2 bolus and Leucovorin 20mg/m2 bolus for 4 days during week 1 and week 5 of radiotherapy, withthree-dimensional conformal pelvic RT 45Gythen boost to residual 5.4 Gyby conventional fractionation. Surgery was done 6{u2013}8 weeks after end of the CRT course. Adjuvant treatment consisted of 4 months FOLFOX4 or XELOX chemotherapy